Cargando…

A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder

INTRODUCTION: We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks of methamphetamine use affect perceived acceptability and preferences. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Karla D., Marks, Charles, Fiuty, Phillip, Harding, Robert W., Page, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433563/
https://www.ncbi.nlm.nih.gov/pubmed/37587515
http://dx.doi.org/10.1186/s13722-023-00401-1
_version_ 1785091675991834624
author Wagner, Karla D.
Marks, Charles
Fiuty, Phillip
Harding, Robert W.
Page, Kimberly
author_facet Wagner, Karla D.
Marks, Charles
Fiuty, Phillip
Harding, Robert W.
Page, Kimberly
author_sort Wagner, Karla D.
collection PubMed
description INTRODUCTION: We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks of methamphetamine use affect perceived acceptability and preferences. METHODS: We conducted qualitative interviews as part of a larger study in 2019–2020. The interview assessed patterns of substance use (including methamphetamine), benefits and drawbacks of methamphetamine use, and interest in a medication to treat MUD. Analysis used an inductive thematic approach, guided by three primary questions: (1) would participants be interested in taking a potential medication for MUD?; (2) what effects would they would like from such a medication?; and (3) what would their ideal treatment route and schedule be (e.g. daily pill, monthly injection)?. RESULTS: We interviewed 20 people reporting methamphetamine use in the past 3 months (10 from Reno, Nevada, USA and 10 from Rio Arriba County, New Mexico, USA). Seven used exclusively methamphetamine, while thirteen used other substances in addition to methamphetamine. Most were enthusiastic about a potential medication to treat MUD. Of those who were not interested (n = 5), all indicated no current concerns about their methamphetamine use. Perceived functional benefits of methamphetamine use (i.e., energy, counteracting opioid sedation, and improved social and emotional wellbeing) informed preferences for a replacement-type medication that would confer the same benefits while mitigating drawbacks (e.g., psychosis, hallucinations, withdrawal). Opinions on preferred dosing varied, with some preferring longer acting medications for convenience, while others preferred daily dosing that would align with existing routines. CONCLUSION: Participants were excited about a potential for a medication to treat MUD. Their preferences were informed by the functional role of methamphetamine in their lives and a desire to maintain the stimulant effects while mitigating harms of illicit methamphetamine. Treatment outcomes that emphasize functioning and wellbeing, rather than abstinence, should be explored.
format Online
Article
Text
id pubmed-10433563
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104335632023-08-18 A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder Wagner, Karla D. Marks, Charles Fiuty, Phillip Harding, Robert W. Page, Kimberly Addict Sci Clin Pract Research INTRODUCTION: We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks of methamphetamine use affect perceived acceptability and preferences. METHODS: We conducted qualitative interviews as part of a larger study in 2019–2020. The interview assessed patterns of substance use (including methamphetamine), benefits and drawbacks of methamphetamine use, and interest in a medication to treat MUD. Analysis used an inductive thematic approach, guided by three primary questions: (1) would participants be interested in taking a potential medication for MUD?; (2) what effects would they would like from such a medication?; and (3) what would their ideal treatment route and schedule be (e.g. daily pill, monthly injection)?. RESULTS: We interviewed 20 people reporting methamphetamine use in the past 3 months (10 from Reno, Nevada, USA and 10 from Rio Arriba County, New Mexico, USA). Seven used exclusively methamphetamine, while thirteen used other substances in addition to methamphetamine. Most were enthusiastic about a potential medication to treat MUD. Of those who were not interested (n = 5), all indicated no current concerns about their methamphetamine use. Perceived functional benefits of methamphetamine use (i.e., energy, counteracting opioid sedation, and improved social and emotional wellbeing) informed preferences for a replacement-type medication that would confer the same benefits while mitigating drawbacks (e.g., psychosis, hallucinations, withdrawal). Opinions on preferred dosing varied, with some preferring longer acting medications for convenience, while others preferred daily dosing that would align with existing routines. CONCLUSION: Participants were excited about a potential for a medication to treat MUD. Their preferences were informed by the functional role of methamphetamine in their lives and a desire to maintain the stimulant effects while mitigating harms of illicit methamphetamine. Treatment outcomes that emphasize functioning and wellbeing, rather than abstinence, should be explored. BioMed Central 2023-08-16 2023 /pmc/articles/PMC10433563/ /pubmed/37587515 http://dx.doi.org/10.1186/s13722-023-00401-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wagner, Karla D.
Marks, Charles
Fiuty, Phillip
Harding, Robert W.
Page, Kimberly
A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title_full A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title_fullStr A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title_full_unstemmed A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title_short A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
title_sort qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433563/
https://www.ncbi.nlm.nih.gov/pubmed/37587515
http://dx.doi.org/10.1186/s13722-023-00401-1
work_keys_str_mv AT wagnerkarlad aqualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT markscharles aqualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT fiutyphillip aqualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT hardingrobertw aqualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT pagekimberly aqualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT wagnerkarlad qualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT markscharles qualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT fiutyphillip qualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT hardingrobertw qualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder
AT pagekimberly qualitativestudyofinterestinandpreferencesforpotentialmedicationstotreatmethamphetamineusedisorder